Fair Value Measurement - Narrative (Details) |
12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023
USD ($)
security
|
Dec. 31, 2022
USD ($)
|
Dec. 31, 2021
USD ($)
|
|
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||
Number of securities in unrealized loss position | security | 20 | ||
Securities in continuous unrealized loss position, less than 12 months | $ 29,100,000 | ||
Securities in continuous unrealized loss position, less than 12 months, accumulated loss | 46,300 | ||
Available-for-sale marketable securities | 217,630,000 | $ 128,599,000 | |
Contingent liability fair value measurement gain | 13,200,000 | 0 | $ 0 |
Antares Pharma, Inc | |||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||
Contingent liability fair value measurement gain | 13,200,000 | ||
Level 3 | |||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||
Available-for-sale marketable securities | $ 0 | $ 0 |